RxDoctor Payments Data

Debra Moses, DO

Family Medicine · Kingwood, TXNPI 1639308398

Payments from drug & device makers

$11,646in general payments, 2019–2025

Across 678 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • GSK$1K
  • Lilly USA, LLC$838
  • AstraZeneca$601
  • Amgen$564
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$11,48599%
  • Education$1611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk95$1,444
AbbVie(2 entities)73$1,078
GSK64$1,039
Lilly USA, LLC48$838
AstraZeneca23$601
Amgen(2 entities)35$564
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$447
Bayer20$414
Otsuka America Pharmaceutical, Inc.24$384
Pfizer19$332
Sanofi-aventis U.S. LLC22$324
Astellas Pharma US Inc16$280
Amarin Pharma, Inc.10$276
Johnson & Johnson(2 entities)17$274
Boehringer Ingelheim16$266
Takeda Pharmaceuticals U.S.A., Inc.14$233
Merck21$229
Radius Health, Inc.12$222
Abbott8$158
Medtronic(2 entities)9$153
Abiomed2$140
Jazz Pharmaceuticals Inc.8$137
Eisai Inc.6$137
Exact Sciences6$132
Dexcom, Inc.8$131
Novartis7$117
Kowa Pharmaceuticals America, Inc.7$113
Vertiflex, Inc.5$90
Esperion Therapeutics, Inc.4$77
Sunovion Pharmaceuticals Inc.5$77
Paratek Pharmaceuticals, Inc.4$70
Idorsia Pharmaceuticals US Inc4$69
Corcept Therapeutics3$66
Inspire Medical Systems, Inc.2$65
Tolmar, Inc.4$62
Bausch Health US, LLC4$59
AMAG Pharmaceuticals, Inc.2$40
Ironwood Pharmaceuticals, Inc2$39
Phathom Pharmaceuticals, Inc.2$39
Currax Pharmaceuticals LLC3$38
Axsome Therapeutics, Inc.2$36
Shield Therapeutics Inc2$36
Shire North American Group Inc2$32
Sumitomo Pharma America, Inc.1$29
Neurocrine Biosciences, Inc.1$27
Lundbeck LLC1$23
Xeris Pharmaceuticals, Inc.1$21
Tandem Diabetes Care, Inc.1$20
Nabriva Therapeutics, PLC1$19
Acella Pharmaceuticals, LLC1$19
Genentech USA, Inc.1$18
Supernus Pharmaceuticals, Inc.1$18
Biohaven Pharmaceuticals, Inc.1$16
Neos Therapeutics, LP1$16
Philips North America LLC1$14
Tris Pharma Inc1$13
Corium, LLC1$13
Scilex Pharmaceuticals Inc.1$13
Adlon Therapeutics L.p.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,646 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$56,833
Medicare patients
127
Services billed
1,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$135,163
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$71,725
JardianceEmpagliflozin45$50,151
Soliqua 100-33Insulin Glargine/Lixisenatide64$43,597
MounjaroTirzepatide31$42,762
JanuviaSitagliptin Phosphate36$39,569
EliquisApixaban33$36,723
RybelsusSemaglutide14$35,317
FarxigaDapagliflozin Propanediol38$31,824
RexultiBrexpiprazole16$30,363
TrulicityDulaglutide19$30,255
MyrbetriqMirabegron27$25,876
ProliaDenosumab14$23,251
EntrestoSacubitril/Valsartan17$21,453
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$21,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,444$170,480115 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$1,039$91,893122 claims
Lilly USA, LLCMounjaro, Trulicity$838$73,01750 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$601$62,04780 claims
Boehringer IngelheimJardiance, Stiolto Respimat$266$59,16660 claims
PfizerEliquis, Abrysvo$332$43,64455 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$324$43,59764 claims
MerckJanuvia$229$39,56936 claims
Otsuka America Pharmaceutical, Inc.Rexulti$384$30,36316 claims
Astellas Pharma US IncMyrbetriq$280$25,87627 claims
AmgenProlia$564$23,25114 claims
NovartisEntresto$117$21,45317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →